Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria

Media Type
Article
Publish or Event Date
Research Institution
University of Maryland School of Medicine
Short Title
Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria
Content Coordinator
Content Manager

A Three-Dose Malaria Vaccine Shows Safety, Efficacy in West African Adults

Media Type
Article
Publish or Event Date
Research Institution
University of Maryland School of Medicine
Short Title
A Three-Dose Malaria Vaccine Shows Safety, Efficacy in West African Adults
Content Coordinator
Content Manager

Monoclonal Antibody Prevents Malaria Infection in African Adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Epidemiology in the Division of Intramural Research

Epidemiology is a core science in public health that includes surveillance, observation, hypothesis testing, analytic research, and experiments and interventions. As the fundamental science of preventive medicine and public health, epidemiology has traditionally focused on disease causation through population studies. Epidemiologists develop and evaluate hypotheses about the effects of genetic, behavioral, environmental, and healthcare factors on human health and develop the knowledge bases for disease prevention and control programs. The field is interdisciplinary and has a methodology distinct from, but dependent on, biostatistics. Epidemiologists incorporate into their research the knowledge base and tools of other disciplines including the biologic sciences, clinical research, and other population sciences.

Main Areas of Focus

While our primary efforts focus on leading research relating to different aspects of infectious disease epidemiology and public health, epidemiologists at NIAID support research of relevance to the mission of NIAID, with approaches that include the following:

  • Design of clinical and population-based studies with appropriate methods and sampling strategies, focusing on reducing study bias and improving data collection
  • Analysis of randomized and non-randomized study cohorts using multivariable methods to identify host and pathogen contributions to infection and disease
  • Application of machine learning and other data science tools to study disease risk factors for selected infectious diseases and immune disorders
  • Molecular techniques to investigate immunological responses to emerging and re-emerging viral diseases
  • Research areas of particular interest include emerging viral pathogens, antimicrobial resistance, nontuberculous mycobacteria, malaria, SARS-CoV-2, Ebola, invasive fungal infections, inborn errors of immunity
Contact Information

Leah Katzelnick, Ph.D, M.P.H. – Seroepidemiology

Jennifer Kwan, Ph.D. – Infectious disease epidemiology, geospatial statistics

Rebecca Prevots, Ph.D. – Epidemiology of nontuberculous mycobacteria

Emily Ricotta, Ph.D., M.Sc. – Infectious disease epidemiology, data management

Content Coordinator
No local navigation
Off

Cornell Professor—Environment Drives Mosquito-borne Diseases

NIAID Now |

Cornell Professor: Environment Drives Mosquito-borne Diseases

NIAID Recognizes World Mosquito Day on Saturday, Aug. 20 

The World Health Organization (WHO) estimates that vector-borne illnesses account for more than 17% of all infectious diseases worldwide and are responsible for more than 700,000 deaths annually. Mosquitoes, which some may argue are the most nefarious among the creepy-crawly swarm of vectors, spread diseases like malaria, dengue, and Zika to humans, causing devastating disease and death worldwide. WHO reports that malaria caused 627,000 deaths in 2020, with the majority being in children younger than five years old. Dengue, also known as breakbone fever, adds another 40,000 to the annual death toll (WHO).

With the growing threat of climate change, researchers are examining how mosquitoes will adapt to warming temperatures and what impact this may have on their ability to transmit pathogens, or disease-causing organisms, to humans.

NIAID-supported researcher Courtney Murdock, Ph.D., associate professor in the Department of Entomology at Cornell University in New York, is researching environmental drivers of malaria transmission and is examining interactions among vectors, pathogens, and vertebrate hosts. She has found that climate change may increase the economic and health burden of vector-borne diseases by altering vectors’ immune responses, increasing their geographic distribution, and modifying their behavior. NIAID spoke with Dr. Murdock to learn more about her research team’s work.

How do environmental factors affect mosquitoes and their ability to transmit disease-causing pathogens?

Because mosquitoes are ectothermic, or cold-blooded, temperature is going to have a big impact on basically all aspects of their life cycle. This is because their internal body temperatures are going to quickly track changes in the ambient temperature. This is going to have important implications for their metabolic rates, physiology, development, survival, activity, and their environments, as well as their overall fitness.

Humidity is also going to be important. Temperature and humidity will affect the desiccation (removal of moisture) stress that an organism experiences. Adult mosquitoes, for example, living in warm, arid environments are going to be subject to more desiccation stress if water is limited than those living in humid, warm environments. In general, the availability of water and temperature constraints are important determinants of mosquito distribution across the globe. If environments are climatically suitable for mosquitoes, mosquito populations could, in theory, be larger. They could persist for longer, and potentially be active for longer periods of the day or season.

Why are warming temperatures expected to expose so many new people to mosquito-borne diseases?

If we’re just talking about temperature and thermal suitability, we would expect that, as temperatures warm in northern latitudes, those environments would become more suitable for disease transmission. But which mosquito-borne diseases will be most affected by climate change? I would expect that it’s going to be diseases that are transmitted by vectors that are active during the daytime—such as Aedes mosquitoes, the vector for dengue, Zika, and other diseases —and not likely at as high of transmission rates as we may see currently in the tropics.

For example, in the U.S, I don’t anticipate malaria becoming a problem in the future because Anopheles mosquitoes bite at night. We have housing with air conditioning, and screens that make it hard for those vectors to get in and get out. So, we interact with mosquitoes in our environments differently than in other areas of the world where vector-borne diseases are currently a big problem, and we have fairly wide access to healthcare resources. Now, in areas where temperatures are currently optimal for transmission, if those temperatures move away from being optimal, you could make predictions that mosquito-borne diseases would decline.

What are the greatest challenges to modeling the effects of warming on mosquito-borne disease transmission?

One of the greatest challenges is the lack of high-quality data that can go into informing some of these models. Specifically, we lack data from a diversity of systems on how environmental variation will impact traits that govern mosquito population dynamics and disease transmission. There are statistical models that are good at prediction for a certain set of scenarios, but these models might breakdown when those scenarios change. Then there are mechanistic models which build in the biology of the system and known relationships, that are good at predicting under change, but are really data hungry. It’s trying to balance the data-hungry nature of these models with the lack of high-quality data that’s a real challenge.

How does your research benefit public health?

I guess the pie-in-the-sky goal for my research program is that the data we generate on how key environmental variables impact mosquito populations and disease transmission will allow us to build more accurate and precise predictive models. These models could then be used in combination with intervention efforts to proactively mobilize intervention efforts or target intervention efforts to regions of the world, or even at a finer scale within a city, to enhance disease control.

Which research projects are you currently working on that you are most excited about?

I have one NIAID-supported project right now that I’m very excited about. It investigates how temperature and relative humidity interact to affect urban malaria transmission. There’s been a lot of work done with temperature, but not other environmental variables. And there’s even less work done looking at how environmental variables interact, and they most definitely will interact. This grant is exciting because it combines large-scale environmental experiments in the lab with the vector and the parasite geared toward defining environmental relationships. We’re then taking these data and putting them into novel, mechanistic models to predict how urban malaria varies seasonally and spatially within a city. The output of this work will help local municipalities be more informed on control efforts.

NIAID is supporting research on climate change’s impact on health.  Funding opportunities can be found on the NIAID website.

 

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

Emily E. Ricotta, Ph.D., M.Sc. (Departed NIAID, March 2024)

Education:

Ph.D., 2018, Swiss Tropical and Public Health Institute, University of Basel, Switzerland

M.Sc., 2012, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Portrait of Emily E. Ricotta, Ph.D., M.Sc.

Subash Babu, M.B.B.S., Ph.D.

  • Host response to helminth infection and pathogenesis of helminthic disease 
  • Modulation of immune responses in co-infections and comorbidities such as tuberculosis (TB), viral infections, undernutrition, obesity, and type 2 diabetes mellitus by helminth infections
  • Immune responses, pathogenesis and biomarker discovery in pulmonary and extrapulmonary TB, and the effect of co-infections and comorbidities (diabetes mellitus. malnutrition, HIV, dengue, and SARS-CoV-2) on TB immunity and pathogenesis
  • Immune responses in and pathogenesis of SARS-CoV-2 infection, adult and pediatric COVID-19 disease, and multi-system inflammatory syndrome in children (MIS-C)
  • Immune responses to vaccination in different populations including Bacille Calmette-Guérin (BCG) vaccination in the elderly and COVID-19 vaccination in all age groups  
Section or Unit Name
Helminth Immunology Section
Exclude from directory
Off
This Researcher/Clinician’s Person Page
Program Description

Dr. Babu’s research focus is on two major thematic areas: 1) immunology of infections and 2) intersection of infectious diseases with metabolic disorders. Our group works on the immunology, pathogenesis, and epidemiology of helminth infections (particularly filariasis, strongyloidiasis, and hookworms), TB, and coexistent infectious diseases (helminths/ viruses and TB). Our group also works on the immunological and clinical outcomes of the interaction between diabetes mellitus (and other metabolic disorders) and TB, helminths (and other infectious diseases). 

Our studies have examined and described 1) the mechanisms underlying the pathogenesis of human W. bancrofti and other helminth infections; 2) the influences of helminth infections on the outcomes of metabolic disorders; 3) the correlates of protective immunity to TB, as well as its diagnostic and prognostic biomarkers; 4) the interface between diabetes mellitus/malnutrition and M. tuberculosis; 5) the immune responses in adult and pediatric COVID-19 and the pathogenesis of MIS-C; and 6) vaccine-engendered immune responses, including BCG and SARS-CoV-2 vaccines.

ICER India

Dr. Babu is the Scientific Director of the NIAID International Center for Excellence in Research (ICER) in India, a collaborative research partnership between NIAID and the Indian Ministry of Health and Family Welfare, specifically the Department of Health Research (DHR) and the Indian Council of Medical Research (ICMR). 

Clinical Studies

ICER202201 Regional Prospective Observational Research in Tuberculosis (RePORT)- Phase 2. (India, USA) Principal Investigator

ICER202101 Adult BCG revaccination induced Antibody and cTfh responses in Latent Tuberculosis individuals with or without diabetes mellitus. (India, Switzerland) Principal Investigator 

ICER202001 A cross-sectional study to estimate the influence of malnutrition, diabetes mellitus and helminth infections on biosignatures in latent tuberculosis in a South Indian population. (India, USA) NCT04526613 Principal Investigator

ICER202002 A pilot study of the effects of helminth infection and SARS-CoV-2 seropositivity on immune response and the intestinal microbiota in India. (India, USA) NCT04813328 Principal Investigator

ICER202003-02  Impact of COVID-19 on clinical manifestations, diagnosis, treatment outcome and immune response for pulmonary tuberculosis - “Associative BRICS Research in COVID-19 and Tuberculosis”. (India, Brazil, South Africa) NCT04930978 Advisor

ICER201701 Effect of Pre-diabetes on Tuberculosis severity. (India, USA) Principal Investigator

ICER201301 Host response to Infection and Treatment in Lymphatic Filarial Disease and Strongyloidiasis in India. (India, USA) NCT00342576 Principal Investigator

ICER201201 Effect of Helminth Infection on Antigen-Specific Immune Responses in Latent Tuberculosis in South India. (India, USA) NCT01547884 Principal Investigator

ICER200901 Characterization of immune responses in pulmonary TB patients who are with or without Diabetes mellitus. (India, USA) NCT01154959 Principal Investigator

ICER200701 Effect of albendazole dose and interval on Wuchereria bancrofti microfilarial clearance in India: a randomized, open label study. (India, USA) NCT00375583 Principal Investigator

ICER201501 Impact of Immune Changes in Pregnancy on Tuberculosis in HIV infected and uninfected women. (India, USA) Associate Investigator 

ICER201401 Effects of Diabetes on Tuberculosis severity. (India, USA) Associate Investigator

ICER200601 The Effect of Parasitic Worm Infections on the Immune Response to Tuberculosis Bacteria (India, USA) NCT00342017 Associate Investigator

ICER200602 Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis (India, USA) NCT00344279 Associate Investigator 

ICER India (Projects within India)
ICER202102 Characterization and Durability of COVID-19 vaccine induced immune responses in healthcare/frontline workers. NCT05049187 Principal Investigator

ICER202003-01 Impact of COVID-19 on clinical manifestations, diagnosis, treatment outcome and immune response for pulmonary tuberculosis. NCT04930978 Principal Investigator

ICER202004 Study to Evaluate the Effectiveness of the BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India. NCT04475302 Principal Investigator

ICER202005 Role of neutralizing antibodies and inflammatory biomarkers in children with Paediatric Inflammatory Multisystem Syndrome - Temporally Associated with SARS-CoV-2 (PIMS-TS). CTRI/2021/01/030605 Principal Investigator

ICER202006 An observational study of clinical and immunological features of children with SARS-COV-2 (COVID-19) infection over a period of 12 to 16 weeks. Principal Investigator

ICER202007 Humoral and cellular immune response among recovered COVID-19 patients: A cross-sectional study, Tiruvallur district and Chennai, Tamil Nadu, India, 2020. Principal Investigator

ICER 202008 A cross sectional study of the systems immunology and viral diversity of SARS-CoV2 infection, COVID-19 disease and Multisystem Inflammatory Syndrome in children. NCT04844242 Principal Investigator

ICER201901 Systems biology and immunology of the effect of tuberculosis chemoprophylaxis in HIV infection. Principal Investigator

ICER201001  Characterization of immune responses in treatment-induced latency in pulmonary tuberculosis. NCT01154959 Principal Investigator

ICER201002 Characterization of immune responses in active tuberculosis infection. Principal Investigator

ICER201003 Characterization of Immune Responses in Tuberculosis Lymphadenitis. Principal Investigator 

ICER202103 Prevalence of cardiopulmonary vascular defects among post-COVID-19 patients using Q-SPECT/CT hybrid imaging and correlation with biomarkers for prognostication – a longitudinal study (POCOS). Associate Investigator

ICER202104 A longitudinal observational study on the impact of SARS-CoV-2 infection on Immune responses to Tuberculosis in children and adolescents (TB COVID KIDS). Associate Investigator 

ICER202009 Role of Vitamin C supplement as an adjunct to tuberculosis treatment in new smear sputum positive pulmonary tuberculosis – An exploratory trial.  Associate Investigator

ICER201702 A Phase IIB Open Label Randomized trial to evaluate the anti-bacterial activity, pharmacokinetics, safety and tolerability of Metformin when given with RIPE in adults with newly diagnosed sputum positive pulmonary tuberculosis: an 8-week study.  Associate Investigator

ICER201703 Phase IIb open label, parallel, randomized controlled trial to assess safety, tolerability, pharmacokinetics & anti-bacterial activity of high dose rifampin vs Conventional dose rifampin in standard anti-TB therapy in drug sensitive Pulmonary TB in adults. Associate Investigator 

ICER201502 Characterization of Immune Responses in Drug Resistant Pulmonary Tuberculosis. Associate Investigator

Selected Publications

Nathella PK, Moideen K, Viswanathan V, Sivakumar S, Ahamed SF, Ponnuraja C, Hissar S, Kornfeld H, Babu S. Heightened microbial translocation is a prognostic biomarker of recurrent tuberculosis. Clin Infect Dis. 2022 Mar 30:ciac236. 

Pavan Kumar N, Padmapriyadarsini C, Rajamanickam A, Marinaik SB, Nancy A, Padmanaban S, Akbar N, Murhekar M, Babu S. Effect of BCG vaccination on proinflammatory responses in elderly individuals. Sci Adv. 2021 Aug 4;7(32):eabg7181. 

Venkataraman A, Kumar NP, Hanna LE, Putlibai S, Karthick M, Rajamanikam A, Sadasivam K, Sundaram B, Babu S. Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India. EBioMedicine. 2021 Apr;66:103317. 

Kumar NP, Kathamuthu GR, Moideen K, Banurekha VV, Nair D, Fay MP, Nutman TB, Babu S. Strongyloides stercoralis Coinfection Is Associated With Greater Disease Severity, Higher Bacterial Burden, and Elevated Plasma Matrix Metalloproteinases in Pulmonary Tuberculosis. J Infect Dis. 2020 Aug 17;222(6):1021-1026. 

Rajamanickam A, Munisankar S, Bhootra Y, Dolla C, Thiruvengadam K, Nutman TB, Babu S. Metabolic Consequences of Concomitant Strongyloides stercoralis Infection in Patients With Type 2 Diabetes Mellitus. Clin Infect Dis. 2019 Aug 1;69(4):697-704.

Anuradha R, George PJ, Pavan Kumar N, Fay MP, Kumaraswami V, Nutman TB, Babu S. Circulating microbial products and acute phase proteins as markers of pathogenesis in lymphatic filarial disease. PLoS Pathog. 2012;8(6):e1002749. 

Visit PubMed for a complete publications listing.

Additional Information
Major Areas of Research
  • Host response to helminth infection and pathogenesis of helminthic disease 
  • Modulation of immune responses in co-infections and comorbidities such as tuberculosis (TB), viral infections, undernutrition, obesity, and type 2 diabetes mellitus by helminth infections
  • Immune responses, pathogenesis and biomarker discovery in pulmonary and extrapulmonary TB, and the effect of co-infections and comorbidities (diabetes mellitus. malnutrition, HIV, dengue, and SARS-CoV-2) on TB immunity and pathogenesis
  • Immune responses in and pathogenesis of SARS-CoV-2 infection, adult and pediatric COVID-19 disease, and multi-system inflammatory syndrome in children (MIS-C)
  • Immune responses to vaccination in different populations including Bacille Calmette-Guérin (BCG) vaccination in the elderly and COVID-19 vaccination in all age groups

Subash Babu, M.B.B.S., Ph.D.

Education:

M.B.B.S., 1993, Govt. Kilpauk Medical College/ University of Madras, India

Ph.D., 1999, University of Connecticut, Storrs, CT

Headshot photograph of Dr. Subash Babu

Monoclonal Antibody Prevents Malaria in U.S. Adults, NIH Trial Shows

One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Jianbing Mu, M.D., Ph.D.

Associate Scientist (Core)

Major Areas of Research

  • Genetic and epigenetic gene regulations in Plasmodium parasites
  • Molecular biology of malaria pathogenesis

Program Description

  • Parasites genetic diversity and associated phenotypes, such as antimalarial drug resistance and parasites virulence factors
  • Epigenetic and epitranscriptomic modifications in parasite development and identification of novel targets for antimalaria drugs or transmission blocking
  • Development of high-sensitivity assay for Plasmodium infection and others

Biography

Dr. Mu received his M.D. from Shanxi Medical University, China, and his Ph.D. from Saitama Medical School, Japan. He then joined NIAID Division of Intramural Research in 2000 and served as visiting fellow, research fellow, and staff scientist. Now, Dr. Mu is an associate scientist in the office of the Chief of Laboratory of Malaria and Vector Research (LMVR), NIAID. His research mainly focuses on the functional genomics of Plasmodium parasites, including the mechanisms of malaria gene regulation, drug responses, immune evasion, and pathogenesis by applying various approaches, such as genetic mapping and genome-wide association (GWA), genetic manipulation, epigenetic and epitranscriptomic modification. Findings from his research include the genome-wide association study to map the loci associated with P. falciparum resistance to antimalarial drugs, epigenetic regulation of antigenic variation in P. falciparum parasites, epitranscriptomic modification in P. falciparum gene regulations and the development of the high-sensitivity assay for Plasmodium infection.

Dr. Mu serves as the Editorial Board member for journals including Current Genomics, Frontiers in Cell and Developmental Biology, and Journal of Tropical Medicine. Dr. Mu received numerous awards, including NIAID Merit Award and Performance Award.

Publications

Liu M*, Guo G*, Qian P*, Mu J*, Lu B, He X, Fan Y, Shang X, Yang G, Shen S, Liu W, Wang L, Gu L, Mu Q, Yu X, Zhao Y, Culleton R, Cao J, Jiang L, Wellems TE, Yuan J, Jiang C, Zhang Q (2022) 5-methylcytosine modification by Plasmodium NSUN2 stabilizes mRNA and mediates the development of gametocytes.Proc Natl Acad Sci U S A. Mar 1;119(9):e2110713119. doi: 10.1073/pnas.2110713119.

Mu J, Yu LL, Wellems TE (2020) Sensitive Immunoassay Detection of Plasmodium Lactate Dehydrogenase by Inductively Coupled Plasma Mass Spectrometry. Front Cell Infect Microbiol. Jan 11;10:620419. doi: 10.3389/fcimb.2020.620419.

Xiao B, Yin S, Hu Y, Sun M, Wei J, Huang Z, Wen Y, Dai X, Chen H, Mu J, Cui L, Jiang L (2019) Epigenetic editing by CRISPR/dCas9 in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):255-260. doi: 10.1073/pnas.1813542116.

Mu J, Andersen JF, Valenzuela JG, Wellems TE (2017) High-Sensitivity Assays for Plasmodium falciparum Infection by Immuno-Polymerase Chain Reaction Detection of PfIDEh and PfLDH Antigens.J Infect Dis. Sep 15;216(6):713-722. doi: 10.1093/infdis/jix369.

Jiang L*, Mu J*, Zhang Q, Ni T, Srinivasan P, Rayavara K, Yang W, Turner L, Lavstsen T, Theander TG, Peng W, Wei G, Jing Q, Wakabayashi Y, Bansal A, Luo Y, Ribeiro JM, Scherf A, Aravind L, Zhu J, Zhao K, Miller LH (2013) PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. .Nature. Jul 11;499(7457):223-7. doi: 10.1038/nature12361. 

Mu J, Myers RA, Jiang H, Liu S, Ricklefs S, Waisberg M, Chotivanich K, Wilairatana P, Krudsood S, White NJ, Udomsangpetch R, Cui L, Ho M, Ou F, Li H, Song J, Li G, Wang X, Seila S, Sokunthea S, Socheat D, Sturdevant DE, Porcella SF, Fairhurst RM, Wellems TE, Awadalla P, Su XZ (2010) Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet. Mar;42(3):268-71. doi: 10.1038/ng.528.

View a complete listing of publications on PubMed.

Tools & Equipment

Sanger sequencing (ABI3730xl) and illumina NextSeq 550 System are available for genotyping, DNA sequencing, whole-genome sequencing and RNA-seq etc.

Section or Unit Name
Malaria Genetics Section
First Name
Jianbing
Last Name
Mu
Exclude from directory
Off
Section/Unit: Year Established
Section/Unit: Location
This Researcher/Clinician’s Person Page
Program Description
  • Parasites genetic diversity and associated phenotypes, such as antimalarial drug resistance and parasites virulence factors
  • Epigenetic and epitranscriptomic modifications in parasite development and identification of novel targets for antimalaria drugs or transmission blocking
  • Development of high-sensitivity assay for Plasmodium infection and others
  • Multi-omic studies on disease vectors, with a focus on ticks and mosquitoes, aimed at identifying biomarkers and advancing vaccine development
Selected Publications

Lee SK, Crosnier C, Valenzuela-Leon PC, Dizon BLP, Atkinson JP, Mu J, Wright GJ, Calvo E, Gunalan K, Miller LH. Complement receptor 1 is the human erythrocyte receptor for Plasmodium vivax erythrocyte binding protein. Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2316304121.

Liu M, Guo G, Qian P, Mu J, Lu B, He X, Fan Y, Shang X, Yang G, Shen S, Liu W, Wang L, Gu L, Mu Q, Yu X, Zhao Y, Culleton R, Cao J, Jiang L, Wellems TE, Yuan J, Jiang C, Zhang Q (2022) 5-methylcytosine modification by Plasmodium NSUN2 stabilizes mRNA and mediates the development of gametocytes. Proc Natl Acad Sci U S A. Mar 1;119(9):e2110713119.

Xiao B, Yin S, Hu Y, Sun M, Wei J, Huang Z, Wen Y, Dai X, Chen H, Mu J, Cui L, Jiang L (2019) Epigenetic editing by CRISPR/dCas9 in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):255-260.

Mu J, Andersen JF, Valenzuela JG, Wellems TE (2017) High-Sensitivity Assays for Plasmodium falciparum Infection by Immuno-Polymerase Chain Reaction Detection of PfIDEh and PfLDH Antigens. J Infect Dis. Sep 15;216(6):713-722.

Jiang L, Mu J, Zhang Q, Ni T, Srinivasan P, Rayavara K, Yang W, Turner L, Lavstsen T, Theander TG, Peng W, Wei G, Jing Q, Wakabayashi Y, Bansal A, Luo Y, Ribeiro JM, Scherf A, Aravind L, Zhu J, Zhao K, Miller LH (2013) PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. Nature. Jul 11;499(7457):223-7.

Mu J, Myers RA, Jiang H, Liu S, Ricklefs S, Waisberg M, Chotivanich K, Wilairatana P, Krudsood S, White NJ, Udomsangpetch R, Cui L, Ho M, Ou F, Li H, Song J, Li G, Wang X, Seila S, Sokunthea S, Socheat D, Sturdevant DE, Porcella SF, Fairhurst RM, Wellems TE, Awadalla P, Su XZ. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet. 2010 Mar;42(3):268-71.

Visit PubMed for a complete publications listing

Additional Information

Tools & Equipment

Dr. Mu oversees the Genomics Core, which is equipped with advanced technologies to facilitate a broad spectrum of genomic and multi-omic studies. These include Sanger sequencing using the ABI3730xl, which provides high-throughput and high-accuracy DNA sequencing for genotyping and targeted DNA analysis. The Illumina NextSeq 550 System enables high-throughput next-generation sequencing (NGS), supporting applications such as whole-genome sequencing, RNA sequencing (RNA-seq), and epigenomics. Additionally, the CosMx Spatial Molecular Imager (SMI) facilitates cutting-edge spatial multiomics analysis, allowing for high-resolution spatial profiling of RNA and protein expression in complex tissues. Together, these platforms provide comprehensive tools for exploring genetic, transcriptomic, and spatial molecular data to address a variety of research questions.

Major Areas of Research
  • Genetic and epigenetic gene regulations in Plasmodium parasites
  • Molecular biology of malaria pathogenesis